The Journal of Infectious Diseases · 1995 · 36 citations · 22 references
Life SciencesInfectious DiseasesPharmacotherapyMolecular VirologyPharmacogeneticsVirologyAntiretroviral TherapyAntiviral AgentsAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyViral MutationAntiviral Resistance MutationsDrug Resistance MutationsHiv Antiretroviral TherapyResistance Mutation DetectionResistance-associated MutationsResistance-associated Viral VariantsResistance-suppressing MutationsReverse Transcriptase Inhibitor Resistance
Human immunodeficiency virus type 1 (HIV-1) isolates from 2 patients who received didanosine (ddI) monotherapy for > 2 years were analyzed for reverse transcriptase (RT) mutations by sequencing of proviral DNA from peripheral blood mononuclear cell cultures. One patient was otherwise antiretroviral-naive; the other had received zidovudine for 5 months before beginning ddI therapy. Isolates obtained from both patients before initiation of ddI monotherapy were free of HIV-1 RT mutations associated with zidovudine or ddI resistance. However, after prolonged ddI monotherapy, mutations associated with zidovudine resistance (M41L, D67N, K70R, and/or T215Y) were detected in HIV-1 isolates from both patients. There was no evidence that surreptitious use of zidovudine or technical artifact caused these findings. This observation suggests that prolonged ddI monotherapy may decrease the efficacy of subsequent zidovudine therapy in some patients.
22
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
Paul A. Volberding, Stephen W. Lagakos, Matthew Koch et al. · New England Journal of Medicine · 1990 · 1.3K citations · Full text